<DOC>
	<DOCNO>NCT00661076</DOCNO>
	<brief_summary>This 3 arm study compare efficacy safety combination therapy PEGASYS + adefovir dipivoxil ( ADV ) versus PEGASYS monotherapy , HBeAg-negative chronic hepatitis B patients.Patients randomize receive 1 ) PEGASYS 180 microgram sc weekly + ADV 10mg po daily 48 week , follow ADV 10mg po monotherapy additional 48 week , 48 week treatment-free follow-up , 2 ) PEGASYS 180 microgram sc weekly + ADV 10mg po daily 48 week , follow 96 week treatment-free follow-up , 3 ) PEGASYS 180 microgram sc monotherapy weekly 48 week , follow 96 week treatment-free follow-up . The anticipated time study treatment 1-2 year , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>ADVANCE Study : A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) + Adefovir Dipivoxil Patients With Hbe ( - ) Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient , 1870 year age ; chronic hepatitis B ; positive HBsAg , positive antiHBe , negative anti HBsAg , negative HBeAg least prior 6 month ; either nucleoside analogue naive , receive IFNa past 6 month . positive hepatitis A , C , D HIV ; history evidence medical condition associate chronic liver disease hepatitis B ; antiviral , antineoplastic immunomodulatory treatment &lt; =6 month prior first dose randomize treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>